Display options
Cite
Nguyen TP, Nguyen TD, Zhu L, et al. Precision Intravenous Immunoglobulin Dosing and Clinical Outcomes: A Retrospective Chart Review. J Clin Neuromuscul Dis. 2021;23(1):18-23doi: 10.1097/CND.0000000000000359.
Nguyen, T. P., Nguyen, T. D., Zhu, L., Ayish, D., Karnik, K., Bokhari, H., & Sheikh, K. A. (2021). Precision Intravenous Immunoglobulin Dosing and Clinical Outcomes: A Retrospective Chart Review. Journal of clinical neuromuscular disease, 23(1), 18-23. https://doi.org/10.1097/CND.0000000000000359
Nguyen, Thy P, et al. "Precision Intravenous Immunoglobulin Dosing and Clinical Outcomes: A Retrospective Chart Review." Journal of clinical neuromuscular disease vol. 23,1 (2021): 18-23. doi: https://doi.org/10.1097/CND.0000000000000359
Nguyen TP, Nguyen TD, Zhu L, Ayish D, Karnik K, Bokhari H, Sheikh KA. Precision Intravenous Immunoglobulin Dosing and Clinical Outcomes: A Retrospective Chart Review. J Clin Neuromuscul Dis. 2021 Sep 01;23(1):18-23. doi: 10.1097/CND.0000000000000359. PMID: 34431797.
Copy Download .nbib Format: NLM
Share it on

J Clin Neuromuscul Dis. 2021 Sep 01;23(1):18-23. doi: 10.1097/CND.0000000000000359.

Precision Intravenous Immunoglobulin Dosing and Clinical Outcomes: A Retrospective Chart Review.

Journal of clinical neuromuscular disease

Thy P Nguyen, Thuy D Nguyen, Liang Zhu, Doha Ayish, Kavitha Karnik, Hammad Bokhari, Kazim A Sheikh

Affiliations

  1. Department of Neurology, McGovern Medical School University of Texas Houston Health Science Center, Houston, TX.
  2. Department of Pharmacy, Memorial Hermann Hospital, Texas Medical Center, Houston, TX.
  3. Department of Internal Medicine, McGovern Medical School University of Texas Houston Health Science Center, Houston, TX; and.
  4. Department of Neurology, Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, AZ.

PMID: 34431797 DOI: 10.1097/CND.0000000000000359

Abstract

OBJECTIVES: Intravenous immunoglobulin (IVIg) is used for treatment of acute neurologic conditions such as Guillain-Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy relapse, and myasthenia gravis exacerbation. Precision dosing (adjusted or ideal body weight) is proposed to conserve IVIg. There have been no published studies comparing clinical outcomes in traditional dosing (actual body weight) with precision dosing. In 2014, our institution began dosing patients with precision dosing. This decision was largely performed by administration rather than physicians' preference. We sought to analyze our retrospective data to understand the change in dosing methods with neurologic outcomes.

METHODS: We performed a retrospective review of all patients hospitalized at a single center who received IVIg for myasthenia gravis, Guillain-Barre syndrome, and chronic inflammatory demyelinating polyradiculoneuropathy from January 2010 to October 2017. We collected baseline information and clinical outcomes including mortality, readmission, need for second rescue treatment, length of stay, discharge disposition, treatment-related adverse events, and modified research council posttreatment sum score.

RESULTS: Length of stay was significantly shorter with precision dosing. There was no statistically significant difference in discharge disposition, readmission, rescue treatment, or modified research council posttreatment sum score with precision dosing.

CONCLUSION: Precision dosing did not adversely affect short-term neurologic outcomes.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Conflict of interest statement

T. P. Nguyen receives royalties from Springer publishing (book author). The remaining authors report no conflicts of interest.

References

  1. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet. 349:225–230, 1997. - PubMed
  2. Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;9:CD001797. - PubMed
  3. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol. 2005;62:1689–1693. - PubMed
  4. Lagasse C, Hatton RC, Pyles E. A survey of intravenous immune globulin (IVIG) dosing strategies. Ann Pharmacother. 2015;49:254–257. - PubMed
  5. Rocchio MA, Hussey AP, Southard RA, et al. Impact of ideal body weight dosing for all inpatient i.v. immune globulin indications. Am J Health Syst Pharm. 2013;70:751–752. - PubMed
  6. Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006;26:813–827. - PubMed
  7. Anderson CR, Olson JA. Correlation of weight-based i.v. immune globulin doses with changes in serum immunoglobulin G levels. Am J Health Syst Pharm. 2015;72:285–289. - PubMed
  8. Sriaroon P, Ballow M. Immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2015;35:713–730. - PubMed
  9. Stump SE, Schepers AJ, Jones AR, et al. Comparison of weight-based dosing strategies for intravenous immunoglobulin in patients with hematologic malignancies. Pharmacotherapy. 2017;37:1530–1536. - PubMed
  10. Immunoglobulin Database Report, Medical Data Solutions and Services. London: Department of Health; 2015:1–31. - PubMed
  11. Nguyen TP, Biliciler S, Wahed A, et al. Occurrence of hemolytic anemia in patients with GBS treated with high-dose IVIg. Neurol Neuroimmunol Neuroinflamm. 2014;1:e50. - PubMed
  12. Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7:ofaa1022020. - PubMed
  13. Hu H, Ma F, Wei X, et al. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2021;42:206. - PubMed
  14. Magellan Rx Management. Medical Pharmacy Trend Report, 2019. 10th ed; 2019. Available at: https://www1.magellanrx.com/documents/2020/03/mrx-medical-pharmacy-trend-report-2019.pdf/. Accessed January 9, 2020. - PubMed
  15. Cornblath DR, Hartung HP, Katzberg HD, et al. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): study design and protocol. J Peripher Nerv Syst. 2018;23:108–114. - PubMed

Publication Types